NASDAQ: PAVMPavmed Inc Stock
$6.30+0.36 (+6.06%)
Updated Jul 1, 2026
PAVM Price
$6.30
Fair Value Price
N/A
Market Cap
$45.82M
52 Week Low
$3.85
52 Week High
$28.44
P/E
-0.17x
P/B
1.16x
P/S
188.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$85.00k
Earnings
-$18.63M
Gross Margin
-227.1%
Operating Margin
-21,890.59%
Profit Margin
-33,477.6%
Debt to Equity
0.52
Operating Cash Flow
-$6M
Beta
1.37
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PAVM Overview
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PAVM's potential to beat the market
- PAVM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PAVM
RankedUnranked of 94
RankedUnranked of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.85 | A | |
| $44.07 | A | |
| $30.65 | A |
Be the first to know about important PAVM news, forecast changes, insider trades & much more!
PAVM News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PAVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PAVM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PAVM is good value based on its book value relative to its share price (1.16x), compared to the US Medical Devices industry average (3x)
P/B vs Industry Valuation
PAVM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PAVM due diligence checks available for Premium users.
Valuation
PAVM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
20.03x
Market
8.54x
PAVM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.16x
Industry
3x
PAVM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PAVM's financial health
Profit margin
Revenue
$22.0k
Net Income
-$60.0k
Profit Margin
-31,763.6%
PAVM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PAVM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$45.4M
Liabilities
$20.4M
Debt to equity
0.52
PAVM's short-term assets ($7.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PAVM's long-term liabilities ($16.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PAVM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PAVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
-$22.0k
Financing
$7.6M
PAVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PAVM vs Medical Device Stocks
Pavmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.